A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Research Opportunity: Understanding the Role of Motor Neurone Disease (MND) Care Coordinators
Researchers from the University of New South Wales are seeking to better understand the role of MND care coordinators, and they need your input.They a...
Research Opportunity: Imaging Research Study in Neuromuscular Disorders
Want to help researchers better identify how neuromuscular disorders like MND affect the brain over time? Researchers from the University of Sy...
Top 5 Frequently Asked Questions from March 2026
The MND NSW InfoLine answers hundreds of questions from people living with MND as well as their families, carers, and health professionals. This blog...
A Letter from PJ Two - Adventuring to Albury
We're always excited to see our MND NSW Puppies go to good homes. So we were especially thrilled to receive this update on the latest adventures that...